Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Phase 1/2 study of VX-445 combination drug in healthy adults and then in people with cystic fibrosis , protocol number VX-445-001

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-445.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    12 weeks

• Mucociliary ClearanceEnrolling

  Cohorts 1 and 2 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis CQBW276X2201

  This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety and tolerability of the inhaled drug QBW276 as well as how the body processes the drug.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    6

  • Length of Participation:

    14 days

• Anti-InflammatoryEnrolling

  Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    189 days

• Anti-InfectiveEnrolling

  Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis , protocol number Savara SAV005

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    12 months

• Nutritional-GIEnrolling

  Phase 2 study of oral glutathione in children with cystic fibrosis , protocol number GROW-IP-16

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug glutathione in children with cystic fibrosis.

  • Age:

    24 Months to 10 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    6 months

• ObservationalEnrolling

  PREDICT: NTM observational study , protocol number NTM-OB-17

  This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

  • Age:

    10 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    20

  • Length of Participation:

    5 years

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.